TRC 150094

Drug Profile

TRC 150094

Alternative Names: T2-mimetic; TRC150094

Latest Information Update: 20 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Torrent Pharmaceuticals
  • Class Antihyperglycaemics; Antihypertensives; Obesity therapies
  • Mechanism of Action Thyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetes mellitus; Dyslipidaemias; Hypertension
  • No development reported Metabolic syndrome

Most Recent Events

  • 07 Jan 2018 Phase-III clinical trials in Diabetes mellitus, Hypertension and Dyslipidaemias (Adjunctive treatment) in India (PO) (CTRI/2017/11/010555)
  • 22 Aug 2017 Torrent Pharmaceuticals plans a phase III trial for Diabetes mellitus, Dyslipidaemias and Hypertension (Adjunctive treatment) (PO) (NCT03254446)
  • 23 Sep 2015 No recent reports on development identified - Phase-I/II for Metabolic syndrome in India and the Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top